Bristol Myers Squibb Co (BMY) stock
BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 15/3031% below fair value
$58.80+0.46 (+0.79%)
Close on Nov 20, 2026Market cap $120.19BP/E 13.0Yield 4.23%
Bristol Myers Squibb free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Bristol Myers Squibb's free cash flow for the twelve months ending Sep 30, 2026 was $9.29B, down 39.3% year over year. For fiscal 2025 it was $12.85B, down 7.9% from the year before. Over ten years it grew 25.9% a year on average. The highest annual figure on record is $15.23B in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.85B | -7.9% |
| FY2024 | Dec 31, 2024 | $13.94B | +10.2% |
| FY2023 | Dec 31, 2023 | $12.65B | +5.9% |
| FY2022 | Dec 31, 2022 | $11.95B | -21.6% |
| FY2021 | Dec 31, 2021 | $15.23B | +14.5% |
| FY2020 | Dec 31, 2020 | $13.30B | +80.3% |
| FY2019 | Dec 31, 2019 | $7.37B | +20.6% |
| FY2018 | Dec 31, 2018 | $6.12B | +44.9% |
| FY2017 | Dec 31, 2017 | $4.22B | +129.0% |
| FY2016 | Dec 31, 2016 | $1.84B | +43.4% |
| FY2015 | Dec 31, 2015 | $1.29B | -51.0% |
| FY2014 | Dec 31, 2014 | $2.62B | -12.8% |
| FY2013 | Dec 31, 2013 | $3.01B | -52.9% |
| FY2012 | Dec 31, 2012 | $6.39B | +42.9% |
| FY2011 | Dec 31, 2011 | $4.47B | +10.0% |
| FY2010 | Dec 31, 2010 | $4.07B | +21.9% |
| FY2009 | Dec 31, 2009 | $3.34B | +20.6% |
| FY2008 | Dec 31, 2008 | $2.77B | +19.7% |
| FY2007 | Dec 31, 2007 | $2.31B | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.84B | -36.0% |
| Q2 FY2026 | Jun 30, 2026 | $3.09B | -13.2% |
| Q1 FY2026 | Mar 31, 2026 | $757.00M | -55.3% |
| Q4 FY2025 | Dec 31, 2025 | $1.60B | -60.5% |
| Q3 FY2025 | Sep 30, 2025 | $5.99B | +13.7% |
| Q2 FY2025 | Jun 30, 2025 | $3.56B | +72.3% |
| Q1 FY2025 | Mar 31, 2025 | $1.69B | -33.6% |
| Q4 FY2024 | Dec 31, 2024 | $4.06B | +3.5% |
| Q3 FY2024 | Sep 30, 2024 | $5.27B | +19.5% |
| Q2 FY2024 | Jun 30, 2024 | $2.06B | +26.8% |
| Q1 FY2024 | Mar 31, 2024 | $2.55B | -5.3% |
| Q4 FY2023 | Dec 31, 2023 | $3.92B | +32.5% |
| Q3 FY2023 | Sep 30, 2023 | $4.41B | +28.2% |
| Q2 FY2023 | Jun 30, 2023 | $1.63B | -18.1% |
| Q1 FY2023 | Mar 31, 2023 | $2.69B | -24.4% |
| Q4 FY2022 | Dec 31, 2022 | $2.96B | -20.8% |
| Q3 FY2022 | Sep 30, 2022 | $3.44B | -31.1% |
| Q2 FY2022 | Jun 30, 2022 | $1.99B | -30.2% |
| Q1 FY2022 | Mar 31, 2022 | $3.56B | -2.5% |
| Q4 FY2021 | Dec 31, 2021 | $3.74B | +21.6% |
| Q3 FY2021 | Sep 30, 2021 | $5.00B | +136.3% |
| Q2 FY2021 | Jun 30, 2021 | $2.85B | -34.7% |
| Q1 FY2021 | Mar 31, 2021 | $3.65B | -2.7% |
| Q4 FY2020 | Dec 31, 2020 | $3.07B | +59.2% |
| Q3 FY2020 | Sep 30, 2020 | $2.11B | -10.7% |
| Q2 FY2020 | Jun 30, 2020 | $4.36B | +130.5% |
| Q1 FY2020 | Mar 31, 2020 | $3.75B | +216.3% |
| Q4 FY2019 | Dec 31, 2019 | $1.93B | -40.9% |
| Q3 FY2019 | Sep 30, 2019 | $2.37B | +124.3% |
| Q2 FY2019 | Jun 30, 2019 | $1.89B | +120.3% |
| Q1 FY2019 | Mar 31, 2019 | $1.19B | +26.7% |
| Q4 FY2018 | Dec 31, 2018 | $3.27B | +278.3% |
| Q3 FY2018 | Sep 30, 2018 | $1.06B | -27.3% |
| Q2 FY2018 | Jun 30, 2018 | $859.00M | -35.7% |
| Q1 FY2018 | Mar 31, 2018 | $936.00M | +64.2% |
| Q4 FY2017 | Dec 31, 2017 | $863.00M | -19.5% |
| Q3 FY2017 | Sep 30, 2017 | $1.45B | – |
| Q2 FY2017 | Jun 30, 2017 | $1.34B | – |
| Q1 FY2017 | Mar 31, 2017 | $570.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.07B | – |
See a number that looks wrong?